R-Ketamine vs. S-Ketamine: Comparing the Differences

Ketamine is a racemic mixture, meaning the drug you encounter in a clinic is actually a fifty-fifty blend of two mirror-image molecules: S-ketamine (esketamine) and R-ketamine (arketamine). These two forms share the same atoms arranged in the same bonds, yet they are non-superimposable reflections of each other, and that geometric difference translates into real pharmacological gaps in how strongly each one grips key brain receptors, what side effects it causes, and how well it fights depression. S-ketamine currently dominates clinical use, but a growing body of research suggests R-ketamine may turn out to be the more interesting molecule for treating mood disorders.

Mirror Images with Different Receptor Grip

The most-discussed pharmacological difference between the two enantiomers is how tightly each one binds the NMDA receptor, a glutamate receptor involved in learning, memory, and synaptic signaling. S-ketamine binds NMDA receptors roughly three to four times more strongly than R-ketamine does.¹ That higher affinity is the reason S-ketamine is a more potent anesthetic and analgesic: it produces about three times stronger pain relief and one-and-a-half times greater anesthetic depth compared with R-ketamine at the same dose.²

For decades, this made S-ketamine seem like the obvious winner. If one enantiomer hits the target harder, clinicians can use a lower dose to achieve the same effect, which should mean fewer side effects. That logic drove the early development of intranasal esketamine for depression. But receptor affinity turned out to be only one piece of a more complicated puzzle.

What Happens Downstream

Blocking the NMDA receptor is how ketamine gets its foot in the door, but the antidepressant response appears to depend on what the brain does next. NMDA blockade on inhibitory interneurons disinhibits excitatory circuits in the prefrontal cortex, leading to a burst of glutamate that activates a different receptor type called AMPA. That AMPA activation sets off a signaling cascade involving BDNF (a protein that supports neuron growth) and a pathway called mTORC1, both of which promote the formation of new synaptic connections.³ Animal studies confirm that when you block AMPA receptors, ketamine’s antidepressant-like effects disappear, and levels of BDNF and mTOR drop back down.⁴

This matters for the S-versus-R debate because the two enantiomers do not trigger these downstream pathways equally. R-ketamine, despite its weaker NMDA grip, appears to engage AMPA-dependent plasticity in ways that produce longer-lasting changes in animal brains. That paradox is part of why the field has shifted attention away from NMDA affinity as the sole predictor of antidepressant potency.

A Metabolite That Changes the Story

Both enantiomers are broken down in the liver into a compound called norketamine, which is then converted into hydroxynorketamine (HNK). The specific metabolite (2R,6R)-HNK, derived primarily from R-ketamine, grabbed headlines when a 2016 study in mice showed it was essential for ketamine’s antidepressant effects and that it worked independently of NMDA receptor blockade, instead acting through early and sustained AMPA receptor activation.⁵ That same study found (2R,6R)-HNK lacked many of ketamine’s typical side effects, including sedation and dissociation.

Follow-up work added nuance. A pharmacological evaluation at clinically relevant concentrations found that (2R,6R)-HNK did not directly bind to or activate AMPA receptors in the way you would expect of a conventional agonist. Instead, it appeared to produce time-dependent increases in the expression of a specific AMPA receptor subunit, suggesting a slower, indirect mechanism rather than a direct receptor switch-flip.⁶ The upshot: (2R,6R)-HNK probably does contribute to antidepressant effects, but the precise mechanism is still under active investigation. The importance of this metabolite, though, tilts the theoretical advantage toward R-ketamine, since R-ketamine is the primary source of (2R,6R)-HNK in the body.

They Light Up Different Brain Regions

Brain imaging adds another layer of distinction. An fMRI study in conscious rats showed that S-ketamine and R-ketamine produce completely different patterns of brain activation. S-ketamine caused a significant positive response in the cortex, nucleus accumbens, and striatum, a pattern very similar to what you see with other NMDA receptor blockers. R-ketamine, by contrast, produced negative fMRI responses across various brain regions, a fundamentally different signature. When the racemic mixture was given, the resulting brain activation pattern looked like S-ketamine’s, suggesting S-ketamine’s signal dominates when the two are combined in equal parts.⁷

This finding has two implications. First, it suggests R-ketamine works through a genuinely different neural circuit than S-ketamine does, not just a weaker version of the same circuit. Second, it raises the question of whether giving the racemic mixture masks R-ketamine’s unique contribution, since S-ketamine’s activation pattern seems to overpower it in the combined drug.

S-Ketamine in the Clinic

S-ketamine has a substantial head start in clinical use. Between 2019 and 2020, an intranasal formulation of esketamine received FDA breakthrough designation and approval for treatment-resistant depression and for major depressive disorder with acute suicidal ideation.⁸ It is typically given alongside an oral antidepressant in a supervised clinical setting.

Real-world evidence supports its effectiveness, particularly for suicidality. In one study of patients at high suicide risk, about 84% of those who were classified as high-risk at baseline were reclassified as lower risk by the end of the esketamine induction phase.⁹ A randomized trial in adolescents with major depression and suicidal ideation found that three doses of intravenous esketamine added to routine inpatient care significantly reduced both suicidal thinking and overall depression scores compared with an active placebo.¹⁰

Despite these results, esketamine’s clinical profile is not uniformly impressive. A systematic review and meta-analysis comparing racemic ketamine head-to-head with esketamine found that racemic ketamine actually demonstrated greater overall response and remission rates and lower dropout rates than esketamine alone.¹¹ That finding complicates the story: if you strip out R-ketamine and just use the S form, you may actually lose some antidepressant benefit.

R-Ketamine’s Preclinical Promise

R-ketamine (arketamine) has not yet been approved for any psychiatric indication, but animal data have been striking. In rodent models of depression, arketamine produces stronger and longer-lasting antidepressant effects than esketamine, with lower abuse potential and fewer psychomotor side effects.¹² That combination of better efficacy and fewer problems is exactly what would make a drug commercially viable if it holds up in humans.

The reduced abuse liability is particularly relevant. S-ketamine’s higher NMDA affinity and its activation of reward-related regions like the nucleus accumbens contribute to its dissociative and psychotomimetic effects, the floating, detached feeling that also makes ketamine attractive for recreational use. R-ketamine produces less of that subjective “high,” which could make it easier to prescribe without the tight supervised-dosing restrictions that currently apply to intranasal esketamine. Early-phase clinical trials of arketamine for depression are underway, though results in humans are still limited.

Side Effects and Dissociation

The side-effect gap between the two enantiomers is one of the most clinically meaningful differences. S-ketamine commonly causes dissociation, dizziness, nausea, and increases in blood pressure, which is why intranasal esketamine must be administered in a certified healthcare setting where patients are monitored for at least two hours afterward. These effects are dose-dependent and related to S-ketamine’s strong NMDA blockade and dopaminergic activity in reward circuits.

R-ketamine, by contrast, appears to carry a lighter side-effect burden in preclinical studies. Its weaker NMDA affinity means less acute dissociation, and its distinct brain activation pattern suggests it does not engage the reward circuitry as aggressively. Animal studies consistently report fewer psychomotor adverse effects with arketamine compared with either esketamine or the racemic mixture.¹² Whether this translates cleanly to human patients remains an open question, but it is one of the strongest arguments in arketamine’s favor.

Anti-Inflammatory Effects and Neurological Applications

R-ketamine has attracted interest beyond depression for its anti-inflammatory properties. In animal models, arketamine suppresses inflammation triggered by bacterial toxins by dialing down a specific signaling molecule (CD38), reducing intracellular calcium, and dampening the activation of microglia and astrocytes, the brain’s resident immune cells. In socially isolated mice, arketamine, but not esketamine, restored activity in the anterior insular cortex and improved cognitive function.¹³

These properties have led researchers to explore arketamine as a potential treatment for neurological conditions including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, disorders where neuroinflammation plays a central role.² These are early-stage investigations, but they illustrate how R-ketamine’s pharmacological profile opens therapeutic doors that S-ketamine’s profile does not. S-ketamine is a good anesthetic and an acute intervention for suicidal crises; R-ketamine may end up being more useful for chronic neuropsychiatric and neurodegenerative conditions.

The Cost Problem with Esketamine

Even setting aside the pharmacological debate, S-ketamine faces a practical barrier: price. A cost-effectiveness analysis projected that over five years, intranasal esketamine increases the fraction of time patients spend in remission from about 25% to 31%, a gain of roughly 0.07 quality-adjusted life years. Total costs, however, rise by around $17,000 per patient, putting the incremental cost-effectiveness ratio above $237,000 per quality-adjusted life year, well above standard willingness-to-pay thresholds used in health economics. At a threshold of $150,000 per quality-adjusted life year, the value-based price of esketamine would need to drop to about $140 per dose, compared with the actual price of roughly $240 per dose at the time of the analysis.¹⁴

Generic racemic ketamine, meanwhile, costs a fraction of branded esketamine and, as noted earlier, shows comparable or possibly superior antidepressant efficacy in head-to-head analyses. This cost gap has fueled a persistent clinical debate: many psychiatrists use off-label intravenous racemic ketamine for depression rather than prescribing the branded intranasal product, partly because the evidence does not clearly justify the price premium. If arketamine eventually reaches the market as a standalone drug, its cost relative to both generic racemic ketamine and branded esketamine will be a major factor in whether it gains traction.

Metabolism and Drug Interactions

Both enantiomers are metabolized by the same set of liver enzymes, primarily CYP2B6, CYP3A4, and CYP2C9, into norketamine, their main active metabolite. Norketamine is then further converted into hydroxynorketamine variants by CYP2B6 and CYP2A6.¹⁵ Because these enzymes are the same ones responsible for processing many common antidepressants, the risk of drug interactions is real. Patients on SSRIs, SNRIs, or other medications that compete for the same enzymes could end up with higher-than-expected ketamine levels, or their other medications could be affected in turn.¹⁶

Genetic variation adds another wrinkle. The CYP enzymes that metabolize ketamine are polymorphic, meaning different people carry different versions of the genes encoding them. Someone who is a poor metabolizer of CYP2B6, for example, will break down ketamine more slowly, leading to higher blood levels and potentially stronger effects and side effects at the same dose. This variability applies equally to both enantiomers, but it becomes especially relevant for esketamine given that it is the one currently being dosed in clinical settings. As personalized dosing strategies develop, genetic testing for these enzyme variants may become part of routine care before prescribing ketamine-based treatments.

Why the “Better” Enantiomer Is Not Settled

The question of which enantiomer is superior depends entirely on what you are trying to accomplish. For acute anesthesia and pain control, S-ketamine wins on potency alone. For rapid reduction of suicidal ideation in a supervised clinical setting, S-ketamine has the regulatory approval and the trial data. But for sustained antidepressant effects with fewer side effects and lower abuse risk, the preclinical evidence leans toward R-ketamine, and the metabolite data suggest that R-ketamine’s downstream products may be doing more of the therapeutic heavy lifting than anyone initially expected.

The field’s trajectory has shifted noticeably. Early development focused almost entirely on S-ketamine because its stronger NMDA binding seemed like the obvious advantage. The discovery that antidepressant action depends more on AMPA-mediated plasticity and metabolite activity than on raw NMDA blockade reshuffled the deck. Clinical trials of arketamine will determine whether the animal data translate, but the pharmacological rationale is strong enough that several groups are actively pursuing it. For patients and clinicians navigating current options, the practical reality is that racemic ketamine and esketamine are both available now, while arketamine remains an investigational agent with a promising but unfinished story.